Vaccination with activated B cells pulsed with tumor-lysates can induce tumor-specific CD4+ T cells in vivo

Immunobiology

Volumn 199, Issue 1, 1998, Pages 133-147

  Ito, Osamu ^a   Harada, Mamoru ^a   Takenoyama, Mitsuhiro ^a   Tamada, Koji ^a   Li, Teili ^a   Abe, Koichiro ^a   Fujie, Hiroshi ^a   Nomoto, Kikuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE ACTIVATION; CANCER IMMUNIZATION; CELL LYSATE; CONTROLLED STUDY; FEMALE; IMMUNIZATION; IRRADIATION; LYMPHOCYTE PROLIFERATION; MELANOMA B16; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SPLEEN LYMPHOCYTE; T LYMPHOCYTE; VACCINATION;

EID: 0031927670     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0171-2985(98)80069-7     Document Type: Article

References (37)

1. BOON, T., J. C. CEROTTINI, E. B. D. VAN, B. P. D. VAN, and P. A. VAN. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12: 337.
2. DYE, E. S., and R. J. NORTH. 1981. T cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases. J. Exp. Med. 154: 1033.
3. FUJIWARA, H., T. HAMAOKA, Y. NISHINO, and M. KITAGAWA. 1977. Inhibitory effect of tumor-bearing state on the generation of in vivo protective immune T cells in a syngeneic murine tumor system. Gann. 68: 589.
4. FUJIMOTO, S., M. I. GREENE, and A. H. SEHON. 1976. Regulation of the immune response to tumor antigens. I. Immunosuppressor cells in tumor-bearing hosts. J. Immunol. 116: 791.
5. TAMAERIUS, J., J. NEPOM, I. HELLSTROM, and K. E. HELLSTROM. 1976. Tumor-associated blocking factors: isolation from sera of tumor-bearing mice. J. Immunol. 116: 724.
6. + T cell activity. J. Immunol. 148: 648.
7. + T-cells show antitumor activity against syngeneic fibrosarcoma. Cancer Res. 53:106.
8. + T cells as Th1 cells based on lymphokine secretion and functional properties. J. Immunol. 144: 4898.
9. MANDELBOIM, O., E. VADAI, M. FRIDKIN, A. KATZ-HILLEL, M. FELDMAN, G. BERKE, and L. EISENACH. 1995. Regression of established murine carcinoma metastases following vaccination with tumor-associated antigen peptides. Nature Med. 1: 1179.
10. ZITVOGEL, L., J. I. MAYORDOMO, T. TJANDRAWAN, A. B. DELEO, M. R. CLARKE, M. LOTZE, and W. J. STORKUS. 1996. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cell, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183: 87.
11. BARKER, A. B., G. MARLAND, B. A. DE, R. J. HUIJBENS, E. H. DANEN, G. J. ADEMA, and C. G. FIGDOR. 1995. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res. 55: 5330.
12. CELLUZZI, C. M., J. I. MAYORDOMO, W. J. STORKUS, M. T. LOTZE, and L. D. J. FALO. 1996. Peptide-pulsed dendritic cells induced antigen-specific, CTL-mediated protective tumor immunity. J. Exp. Med. 183: 282.
13. PAGLIA, P., C. CHIODONI, M. RODOLFO, and M. P. COLOMBO. 1996. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183: 317.
14. + T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells. Int. J. Cancer 58: 69.
15. + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J. Exp. Med. 181: 619.
16. CHESNUT, R. W., S. M. COLON, and H. M. GREY. 1982. Antigen presentation by normal B cells, B cell tumors, and macrophages: functional and biochemical comparison. J. Immunol. 128: 1764.
17. KIEGER, J. I., S. F. GRAMMER, H. M. GREY, and R. W. CHESNUT. 1985. Antigen presentation by splenic B cells: resting B cells are ineffective, whereas activated B cells are effective accessory cells for T cell responses. J. Immunol. 135: 2937.
18. FREEMAN, G. J., J. G. GRIBBEN, V. A. BOUSSIOTIS, J. W. NG, V. J. RESTIVO, L. A. LOMBARD, G. S. GRAY, and L. M. NADLER. 1993. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 262: 909.
19. DAMLE, N. K., K. KLUSSMAN, P. S. LINSLEY, A. ARUFFO, and J. A. LEDBETTER. 1992. Differential regulatory effects of intercellular adhesion molecule-1 on costimulation by the CD28 counter-receptor B7. J. Immunol. 149:2541.
20. LIU, Y. and C. J. JANEWAY. 1991. Microbial induction of co-stimulatroy activity for CD4 T-cell growth. Int. Immunol. 3: 323.
21. AZUMA, M., D. ITO, H. YAGITA, K. OKUMURA, J. H. PHILLIPS, L. L. LANIER, and C. SOMOZA. 1993. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 366: 76.
22. OKAMOTO, T, M. HARADA, Y. SHINOMIYA, G. MATSUZAKI, and K. NOMOTO. 1995. The antitumor effect of tumor-draining lymph node cells activated by both anti-CD3 monoclonal antibody and activated B cells as costimulatory-signal-providing cells. Cancer Immunol. Immunother. 40: 173.
23. HARADA, M., T. OKAMOTO, S. KUROSAWA, Y. SHINOMIYA, O. ITO, M. TAKENOYAMA, H. TERAO, G. MATSUZAKI, G. KIMURA, and K. NOMOTO. 1995. The antitumor activity induced by the in vivo administration of activated B cells bound to anti-CD3 monoclonal antibody. Cell. Immunol. 161: 132.
24. TAMADA, K., M. HARADA, T. OKAMOTO, M. TAKENOYAMA, O. ITO, G. MATSUZAKI, and K. NOMOTO. 1995. Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antobody and activated B cells and then in a culture with interleukin-2. Cancer Immunol. Immunother. 41: 339.
25. ITO, O., M. HARADA, M. TAKENOYAMA, H. SUMICHIKA, G. MATSUZAKI, and K. NOMOTO. 1996. An increase of B cells in the tumor-bearing state has the potential to induce anti-tumor immunity. Immunobiology 195: 1.
26. + T cells. Immunobiology 193: 439.
27. ASHWELL, J. D., M. K. JENKINS, and H. R. SCHWARTZ. 1988. Effect of gamma radiation on resting B lymphocytes. II. Functional characterization of the antigen-presentation defect. J. Immunol. 141: 2536.
28. CHESNUT, R. W., S. M. COLON, and H. M. GREY. 1982. Requirements for the processing of antigens by antigen-presenting B cells. I. Functional comparison of B cells tumors and macrophages. J. Immunol. 129: 2382.
29. ST, P. Y., and T. H. WATTS. 1990. MHC class II-restricted presentation of native protein antigen by B cells is inhibitable by cycloheximide and Brefeldin. A. J. Immunol. 145: 812.
30. KUROSAWA, S., M. HARADA, G. MATSUZAKI, Y. SHINOMIYA, H. TERAO, N. KOBAYASHI, and K. NOMOTO. 1995. Early-appearing tumour-infiltrating natural killer cells play a crucial role in the generation of anti-tumour T lymphocytes. Immunology 85: 338.
31. LAKEY, E. K., L. A. CASTEN, W. L. NIEBLING, E. MARGOLIASH, and S. K. PIERCE. 1988. Time dependence of B cells processing and presentation of peptide and native protein antigens. J. Immunol. 140: 3309.
32. ASHWELL, J. D. 1988. Are B lymphocytes the principal antigen-presenting cells in vivo?. [Review]. J. Immunol. 140: 3697.
33. THOMPSON, C. B., T. LINDSTEN, J. A. LEDBETTER, KUNKEL, S. L., H. A. YOUNG, S. G. EMERSON, J. M. LEIDEN, and C. H. JUNE. 1989. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc. Natl. Acad. Sci. USA 86: 1333.
34. GIMMI, C. D., G. J. FREEMAN, J. G. GRIBBEN, K. SUGITA, A. S. FREEDMAN, C. MORIMOTO, and L. M. NADLER. 1991. B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferative and secrete interleukin 2. Proc. Natl. Acad. Sci. USA 88: 6575.
35. KURT, J. E., D. LIANO, K. A. HAYGLASS, B. BENACERRAF, M. S. SY, and A. K. ABBAS. 1998. The role of antigen-presenting B cells in T cell priming in vivo. Studies of B cells-deficient mice. J. Immunol. 140: 3773.
36. + T cells to protein antigens in vivo. J. Immunol. 155: 3734.
37. SCHULTZ, K. R., J. P. KLARNET, R. S. GIENI, K. T. HAYGLASS, and P. D. GREENBERG. 1990. The role of B cells for in vivo T cell responses to a Friend virus-induced leukemia. Science 249: 921.